ANCN News

Levi Strauss (LEVI) is bringing its blue jeans back to public markets. This week the company filed for an IPO that we estimate could raise $750 million, coming as early as March. It's no wonder Levi is going public, based on its 2017 and 2018 financials, which saw sales growth of 8% and 14%, respectively. That's especially impressive given the current...read more

Anchiano Therapeutics, a late-stage biotech developing therapies for early-stage bladder cancer, raised $31 million by offering 2.7 million ADSs at $11.50, below the expected price of $14.55. At $11.50, Anchiano Therapeutics would command a market cap of $78 million. The company previously filed to raise $35 million by offering 2.4 million ADSs at $14.55.  Anchiano...read more

Railroad IPOs were hot in the 1850's, but two billionaires are bringing the industry back this week with an offering of Virgin Trains USA. In total, the week could see up to seven deals, but Virgin Trains USA's $510 million IPO is larger than the other six combined. These others are mostly small healthcare IPOs: ...read more

Anchiano Therapeutics, a Phase 3 biotech developing therapies for early-stage bladder cancer, announced terms for its IPO on Thursday. The Jerusalem, Israel-based company plans to raise $35 million by offering 2.4 million ADSs at a price of $14.55, the as-converted last close of its shares listed on the TASE($2.91), at five shares per ADS. Insiders intend to purchase $17.5...read more